+86-571-64286222

SERVICE
Hotline
+86-571-64286222
Customer service team:
Service
Service time:
9:00 - 17:00

MOBILE

WECHAT

AD:No.112 Jianduan Road, Tonglu, Zhejiang, China.

PC:311500


©2018 TONGLU YOUSHI MEDICAL INSTRUMENT CO., LTD. COPYRIGHT     浙ICP备10215171号  POWERED BY WWW.300.CN

TEL:

86-571-64286222

News

Company news
Trade news

2018 outlook for the medical device and diagnostics industry

[Abstract]:
It is expected that the sales of medical technology (including medical instruments and diagnostic products) will reach US$440 billion in 2018 (CAGR: +4.4% in 2011-2018).

It is expected that the sales of medical technology (including medical instruments and diagnostic products) will reach US$440 billion in 2018 (CAGR: +4.4% in 2011-2018).

The growth rate of medical technology sales in 2011-2018 is expected to exceed the prescription drug market, CAGR: +4.4% vs +2.5%

It is expected that the company with the largest sales volume in medical technology in 2018 will be Johnson & Johnson. The company's global medical technology sales will reach 37.8 billion US dollars.

It is expected that in vitro diagnostics will become the largest category of sales in medical technology in 2018 with sales of $54.5 billion.

By 2018, it is estimated that the global R&D expenditure in medical technology will reach 25.3 billion U.S. dollars with an annual growth rate of 3.3% (CAGR).

It is expected that the most costly medical technology company in 2018 will be Johnson & Johnson and R&D expenditure is expected to reach US$2.1 billion.

The number of PMA approvals for the first time in 2011 was 43, which was a 95% increase over the previous year; the number approved for 510-K was 3145, an increase of 10% over the previous year

As of now, the number of PMA approvals for the first time in 2012 is 24, of which 10 are IVD products and 7 are cardiac products.

In 2018, Roche will be the leader in the in vitro diagnostic market with annual sales of $9.9 billion and a market share of 18%.

In 2018, Medtronic will continue to maintain its position as the world's No. 1 global leader in heart products, with global sales of 10.4 billion U.S. dollars and a market share of 21%.

After the acquisition of Synthes in June 2012, Johnson & Johnson is expected to become the dominant orthopedic market in 2018 with a market share of 30%.

In the first half of 2012, the amount of M&A transactions in the medical technology sector decreased by 46% compared to the same period of last year, the number of transactions decreased by 42%, and total risk financing transactions increased by 9% to US$1.9 billion.